한국지질동맥경화학회 학술대회

Evolving LDL-C management: guidelines and the role of evolocumab

Is LDL-C goal attainment enough? pitavastatin/fenofibrate in mixed dyslipidemia

Bridging guidelines and practice: strategic implementation of combination therapy in lipid management

Paving the road for optimal LDL-C management: new evidence on intensive LDL-C targeting from the Ez-PAVE trial

The role of DPP-4 inhibitors in Korean diabetes care: focusing on K-evidence

The smaller the better: rovazet

Bempedoic acid: LDL-C lowering beyond statins - evidence and clinical role

Optimizing non-statin therapy: PCSK9 inhibitors and inclisiran

Emerging Lp(a)-lowering therapies: siRNA, ASO, and beyond

Lipid-lowering therapy in people living with HIV (PLWH)

Lipid-lowering therapy in cancer patients and survivors

Lipid-lowering therapy in patients with CKD

Cardiovascular prevention in hemodialysis: is omega-3 back?

Ion channels in atherosclerosis: from calcium flux to vascular dysfunction

Energy metabolism and lipid oxidation in cardiometabolic pathophysiology

Lp(a): from lipoprotein biology to atherosclerotic cardiovascular disease

Lipoprotein(a): the next frontier in cardiovascular prevention

Medicine in art (그림 속의 의학)

Start early: upfront combination therapy for faster LDL-C goal attainment in the CKM era

Start strong: elevating LDL-C management in ASCVD with high-dose atorvastatin plus ezetimibe

Beyond the statin, ROSUZET; start early, switch now

Be the standard ROSUZET; evidence-driven lipid management

Integrated management of hypertension and dyslipidemia for cardiovascular disease prevention

TBD (Lecture Title)

Rethinking LDL-C strategies in the aLLT era: transforming effective control into reality with leqvio cases

TBD (Lecture Title)

Clinical updates in dyslipidemia: positioning baroezet for optimal patient care

TBD (Lecture Title)

The quiet signal, no longer - triglyceride at the crossroads of insulin resistance and cardiometabolic risk

The health information on social media: the reliability and professionals’ responsibility

Sex differences in lipid profiles and residual cardiovascular risk

Early-onset dyslipidemia in young adults: screening strategies and lifetime ASCVD risk assessment

Menopause and cardiometabolic transition: optimizing lipid management in midlife women

Korean epidemiology and risk modifiers for establishing LDL-C goal strategies

Practical algorithm for intensive lipid lowering therapy in the 2026 Korean guidelines

Nutritional management and lifestyle modification tailored to the Korean dietary pattern

Optimized lipid management for special populations

Lipoprotein(a) in Korean patients: real-world data, cardiovascular risk, and clinical implications

Lipoprotein(a) and coronary atherosclerosis in Vietnam: real-world data and emerging cardiovascular risk

Measuring Lipoprotein(a) in clinical practice: assay challenges, standardization, and interpretation

Evolution of vulnerable plaques: from natural history to preventive intervention

High-risk plaque features on CCTA: identification and clinical implications

Intravascular imaging of vulnerable plaques: insights from IVUS and OCT

Coronary physiology and plaque vulnerability: integrative relationship and prognostic implications

Fatty liver and residual cardiovascular risk: epidemiology and clinical implications

From lipotoxicity to atherosclerosis: MASLD/MetALD subtypes and cardiovascular risk

Therapeutic strategies for cardiometabolic risk reduction in MASLD

Closing the gap between guidelines and reality in dyslipidemia management

PCSK9 inhibition in primary prevention: insights from VESALIUS-CV and clinical implications

Low LDL-C and brain safety: risk of hemorrhagic stroke and cognitive dysfunction

Early combination therapy in primary prevention

CETP inhibition revisited: obicetrapib for LDL-C reduction and ASCVD risk management

APOC3 inhibition: targeting triglyceride-rich lipoproteins and residual risk

ANGPTL3 inhibition: expanding therapeutic opportunities beyond LDL-C

Defining residual cardiovascular risk in the post-LDL era: unmet needs and mechanisms

Targeting residual risk: Lp(a), triglyceride-rich lipoproteins, and inflammation

Beyond less is more: navigating residual thrombotic and inflammatory risk in AF and stable CAD

Lipid remodeling of adipose tissue: the hidden link between obesity and atherosclerosis

Remnant cholesterol and residual cardiovascular risk in obesity

Dual targeting of lipid and weight: emerging therapies and clinical strategies